{"id":155261,"date":"2026-11-03T20:47:06","date_gmt":"2026-11-03T20:47:06","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/155261\/"},"modified":"2026-11-03T20:47:06","modified_gmt":"2026-11-03T20:47:06","slug":"fda-approval-for-lamprene-issued-to-novartis","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/155261\/","title":{"rendered":"FDA Approval for LAMPRENE issued to NOVARTIS"},"content":{"rendered":"<p>What this release says<\/p>\n<p class=\"mt-2 max-w-[72ch] text-[14.5px] leading-relaxed text-muted-foreground\">The FDA approved a labeling change (SUPPL-15) to Novartis&#8217;s NDA 019500 for LAMPRENE, with the approval dated 11\/03\/2026. The filing does not describe what the labeling change covers, and the label itself is not available on the FDA site. Both LAMPRENE strengths are listed as discontinued, so this approval has limited direct bearing on current sales for a shareholder.<\/p>\n<p>Key figures<\/p>\n<p>Original approval date12\/15\/1986<\/p>\n<p>Latest supplement approval11\/03\/2026<\/p>\n<p>Active ingredient strengths50MG and 100MG<\/p>\n<p>Negative for shareholdersBoth LAMPRENE strengths are listed as discontinued.<\/p>\n<p class=\"mt-4 flex items-center gap-1.5 text-[11.5px] text-dim-foreground\">Written by Quantisnow AI from this release. Not financial advice.<\/p>\n<p>This insight was delivered by <a rel=\"publisher nofollow noopener\" itemprop=\"url\" class=\"font-medium text-foreground transition-colors hover:text-brand-glow\" href=\"https:\/\/www.quantisnow.com\/\" target=\"_blank\">Quantisnow<\/a> &#8211; Wall Street&#8217;s wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track <a class=\"underline decoration-dotted underline-offset-2 transition-colors hover:text-brand-glow\" href=\"https:\/\/www.quantisnow.com\/company\/NVS\" rel=\"nofollow noopener\" target=\"_blank\">NVS (Novartis AG)<\/a> and more on Quantisnow.<\/p>\n","protected":false},"excerpt":{"rendered":"What this release says The FDA approved a labeling change (SUPPL-15) to Novartis&#8217;s NDA 019500 for LAMPRENE, with&hellip;\n","protected":false},"author":2,"featured_media":155262,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[127],"tags":[206,9959,72686],"class_list":["post-155261","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novartis","tag-novartis","tag-nvs","tag-quantisnow"],"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/155261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=155261"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/155261\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/155262"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=155261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=155261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=155261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}